Clinical Trial Update: A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating ESG206, an anti-BAFF-R monoclonal antibody, for Primary Sjögren's syndrome, with the study currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjögren Syndrome

Drugs mentioned

• ESG206

Snippet

Sponsor: Shanghai Escugen Biotechnology Co., Ltd | Conditions: Primary Sjögren Syndrome | Phase 2 | Status: NOT_YET_RECRUITING